ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

NEUROSCIENCE RESEARCH, published by Elsevier Ireland Ltd, is a leading journal in the field of neuroscience, with a notable reputation for disseminating high-quality research that spans a variety of topics within the discipline. With an ISSN of 0168-0102 and an E-ISSN of 1872-8111, this journal serves as a vital platform for both established researchers and emerging voices in the field. Ranking in the Q2 quartile in both Medicine and Neuroscience categories, it has been recognized as a reliable source of innovative findings since its inception in 1984, with continuous publication through 2024. Although it does not currently offer Open Access options, the journal is indexed in Scopus, holding a significant position at Rank #48/113 in General Neuroscience, reflecting its contribution to advancing the understanding of neural mechanisms across various contexts. With its address anchored in Ireland, NEUROSCIENCE RESEARCH plays an essential role in bridging scientific inquiry and practical applications, making it an indispensable resource for researchers, professionals, and students dedicated to the burgeoning field of neuroscience.

NATURE REVIEWS NEUROSCIENCE is a prestigious journal published by NATURE PORTFOLIO, renowned for its commitment to advancing the field of neuroscience. Since its inception in 2000, it has become a significant platform for disseminating comprehensive reviews and insights that shape the understanding of neurological science. With an impressive Scopus ranking of #2 out of 113 in the General Neuroscience category, this journal consistently engages the top 2% of researchers and professionals in the field, underscoring its impactful contributions. The journal not only provides a forum for high-quality reviews but also bridges emerging research trends with established knowledge, fostering a robust discourse among scholars and practitioners. As a Q1 journal in Neuroscience (miscellaneous), NATURE REVIEWS NEUROSCIENCE offers invaluable access to critical research developments, making it an essential resource for students, researchers, and professionals aiming to stay at the forefront of neuroscience advancements. Explore the latest findings and engage with a global community dedicated to unraveling the complexities of the nervous system.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

NEUROSCIENTIST is a leading journal in the field of clinical neurology and neuroscience, published by SAGE Publications Inc. With an impressive impact factor reflected in its Q1 quartile ranking in both clinical neurology and miscellaneous neuroscience as of 2023, this journal positions itself as a crucial platform for the latest research and advancements in the neural sciences. Spanning from 1995 to 2024, NEUROSCIENTIST features a range of high-quality, peer-reviewed articles that cater to researchers, practitioners, and students alike. Although it does not offer Open Access options, the journal remains a vital resource owing to its Scopus rankings, situating it within the top percentile of its categories: ranked #28 out of 400 in clinical neurology and #15 out of 113 in general neuroscience. The journal's commitment to disseminating significant findings underlines its importance in fostering advancements in neurological understanding and treatment.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.